on Applied DNA Sciences, Inc.
Applied DNA Sciences, Inc. Partners with HDT Bio to Enhance Rapid Vaccine Production
Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, has been awarded a contract by HDT Bio to advance rapid vaccine development. This collaboration, under the ‘Project NextGen: Enabler’ initiative, aims to significantly shorten vaccine production times to meet critical needs during health crises.
The contract involves Applied DNA supplying Linea™ DNA IVT templates for use with HDT Bio’s LION™ repRNA vaccination platform. The primary goal is to prove that it is feasible to manufacture 1,000 doses of a functional vaccine within just seven days, a crucial capability during outbreaks or pandemics. This effort represents a pivotal step towards decentralized and accelerated vaccine manufacturing.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Applied DNA Sciences, Inc. news